Survival After Invasive or Conservative Management of Stable Coronary Disease
Circulation · 03.01.2023 · 147 (1) · 8-19
DOI: 10.1161/circulationaha.122.062714 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Circulation, erschienen am 03.01.2023. Verfasst von Judith S Hochman und 30 weiteren Autor:innen. Beteiligte Einrichtung: NYU Grossman School of Medicine, New York, NY (J.S.H., R.A., H.R.R., S.B., Y.X., S.M., M.C., A.C., J.D.N., J.S.B., A.B.T.). Hauptthemen laut MEDLINE: Coronary Artery Disease, Acute Coronary Syndrome. Die Arbeit wurde bisher 157-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS, HHS | NIH | National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Background
The ISCHEMIA trial (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) compared an initial invasive versus an initial conservative management strategy for patients with chronic coronary disease and moderate or severe ischemia, with no major difference in most outcomes during a median of 3.2 years. Extended follow-up for mortality is ongoing.
Methods
ISCHEMIA participants were randomized to an initial invasive strategy added to guideline-directed medical therapy or a conservative strategy. Patients with moderate or severe ischemia, ejection fraction ≥35%, and no recent acute coronary syndromes were included. Those with an unacceptable level of angina were excluded. Extended follow-up for vital status is being conducted by sites or through central death index search. Data obtained through December 2021 are included in this interim report. We analyzed all-cause, cardiovascular, and noncardiovascular mortality by randomized strategy, using nonparametric cumulative incidence estimators, Cox regression models, and Bayesian methods. Undetermined deaths were classified as cardiovascular as prespecified in the trial protocol.
Results
Baseline characteristics for 5179 original ISCHEMIA trial participants included median age 65 years, 23% women, 16% Hispanic, 4% Black, 42% with diabetes, and median ejection fraction 0.60. A total of 557 deaths accrued during a median follow-up of 5.7 years, with 268 of these added in the extended follow-up phase. This included a total of 343 cardiovascular deaths, 192 noncardiovascular deaths, and 22 unclassified deaths. All-cause mortality was not different between randomized treatment groups (7-year rate, 12.7% in invasive strategy, 13.4% in conservative strategy; adjusted hazard ratio, 1.00 [95% CI, 0.85–1.18]). There was a lower 7-year rate cardiovascular mortality (6.4% versus 8.6%; adjusted hazard ratio, 0.78 [95% CI, 0.63–0.96]) with an initial invasive strategy but a higher 7-year rate of noncardiovascular mortality (5.6% versus 4.4%; adjusted hazard ratio, 1.44 [95% CI, 1.08–1.91]) compared with the conservative strategy. No heterogeneity of treatment effect was evident in prespecified subgroups, including multivessel coronary disease.
Conclusions
There was no difference in all-cause mortality with an initial invasive strategy compared with an initial conservative strategy, but there was lower risk of cardiovascular mortality and higher risk of noncardiovascular mortality with an initial invasive strategy during a median follow-up of 5.7 years. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04894877.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- NYU Grossman School of Medicine, New York, NY (J.S.H., R.A., H.R.R., S.B., Y.X., S.M., M.C., A.C., J.D.N., J.S.B., A.B.T.).
- Duke Clinical Research Institute, Durham, NC (S.M.O., R.D.L., D.B.M.).
- National Institutes of Health, Bethesda, MD (Y.R., R.K.).
- All India Institute of Medical Sciences, New Delhi (B.B.).
- Northwick Park Hospital, London, United Kingdom (R.S., A.B.).
- Imperial College London and Royal Brompton Hospital, United Kingdom (R.S.).
ORCID-Profile: Judith S Hochman, Harmony R Reynolds, Sripal Bangalore, Roxy Senior, Shaun G Goodman, Renato D Lopes, Radosław Pracoń, José López-Sendón, Aldo Pietro Maggioni, Jonathan D Newman, Jeffrey S Berger, Harvey D White, Robert A Harrington, Gregg W Stone, Daniel B Mark, John A Spertus, David J Maron
Förderung
- NHLBI NIH HHS
- NCATS NIH HHS
- HHS | NIH | National Heart, Lung, and Blood Institute
Zitieren
APA
Hochman, J. S., Anthopolos, R., Reynolds, H. R., Bangalore, S., Xu, Y., O'Brien, S. M., Mavromichalis, S., Chang, M., Contreras, A., Rosenberg, Y., Kirby, R., Bhargava, B., Senior, R., Banfield, A., Goodman, S. G., Lopes, R. D., Pracoń, R., López-Sendón, J., Maggioni, A. P., …, & ISCHEMIA-EXTEND Research Group (2023). Survival After Invasive or Conservative Management of Stable Coronary Disease. Circulation, 147(1), 8-19. https://doi.org/10.1161/circulationaha.122.062714
Vancouver
Hochman JS, Anthopolos R, Reynolds HR, Bangalore S, Xu Y, O'Brien SM, et al. Survival After Invasive or Conservative Management of Stable Coronary Disease. Circulation. 2023;147(1):8-19. doi:10.1161/circulationaha.122.062714
BibTeX
@article{Hochman2023,
author = {Hochman, Judith S and Anthopolos, Rebecca and Reynolds, Harmony R and Bangalore, Sripal and Xu, Yifan and O'Brien, Sean M and Mavromichalis, Stavroula and Chang, Michelle and Contreras, Aira and Rosenberg, Yves and Kirby, Ruth and Bhargava, Balram and Senior, Roxy and Banfield, Ann and Goodman, Shaun G and Lopes, Renato D and Pracoń, Radosław and López-Sendón, José and Maggioni, Aldo Pietro and Newman, Jonathan D and Berger, Jeffrey S and Sidhu, Mandeep S and White, Harvey D and Troxel, Andrea B and Harrington, Robert A and Boden, William E and Stone, Gregg W and Mark, Daniel B and Spertus, John A and Maron, David J and ISCHEMIA-EXTEND Research Group, ISCHEMIA-EXTEND Research Group},
title = {Survival After Invasive or Conservative Management of Stable Coronary Disease},
journal = {Circulation},
year = {2023},
volume = {147},
number = {1},
pages = {8--19},
doi = {10.1161/circulationaha.122.062714}
}
EUVIMED